Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|December 5, 2016
- December 2016 Heart Health
- Volume 82
- Issue 12
OTC Product News (December 2016)
Read about the new OTC products featured in December 2016.
Advertisement
Salonpas Lidocaine 4% Pain Relieving Gel-Patch
Marketed by: Hisamitsu America
Hisamitsu America has launched its new topical analgesic solution, Salonpas Lidocaine 4% Pain Relieving Gel-Patch for consumer retail to provide temporary relief of aches and pains in the back, neck, shoulders, knees, and elbows.
For More Information: salonpas.us
Stopain Migraine Topical Pain-Relieving Gel
Marketed by: Troy Healthcare, LLC
Troy Healthcare’s newest product, Stopain Migraine, is a topical pain-relieving gel that is massaged onto the back of the neck and behind each ear. It can be reapplied after 30 minutes and used up to 4 times daily.
For More Information: stopainmigraine.com
Jet-Avert
Marketed by: Bell Pharmaceuticals
Bell Pharmaceuticals has launched Jet-Avert motion sickness tabs for consumer retail. Jet-Avert provides all-day protection from nausea, dizziness, and vomiting, and is available in 24- and 100-count sizes.
For More Information: jet-avert.com
Almond Protein Powder
Marketed by: Almond Pro
Almond Pro has announced the launch of its Almond Protein Powder, which will be available over the counter in chocolate and vanilla flavors. Almond Protein Powder contains 19 g of almond protein, 6 g of natural fiber, and 14 essential vitamins and minerals.
For More Information: almondpro.com
Articles in this issue
almost 10 years ago
Recent Safety Data: Implications for Use of Proton Pump Inhibitorsalmost 10 years ago
Case Studies (December 2016)almost 10 years ago
Can You Read These Rxs? (December 2016)almost 10 years ago
Pet Peeves (December 2016)almost 10 years ago
US Generics Market Forecasted to Grow from 2016 to 2020almost 10 years ago
Generic Product News (December 2016)almost 10 years ago
Meeting Patients Where They Arealmost 10 years ago
Managing Workplace Changealmost 10 years ago
Comprehensive Addiction and Recovery Act of 2016Advertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5